Pyrotinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:a Randomised, Double-blind, Multicentre, Phase 3 Trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Capecitabine (Primary) ; Pyrotinib (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 18 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2016 New trial record